Sign In
Buy IRWD
$3.24
-0.0400 (-1.22%)
At Close: Jun 03, 2026
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
12:31pm, Friday, 27'th Mar 2026
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells $20,528,940.00 in Stock
04:26am, Friday, 20'th Mar 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) Director Alexander Denner sold 6,730,800 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold a
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
01:35pm, Thursday, 12'th Mar 2026
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
09:25am, Friday, 06'th Mar 2026
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
04:05pm, Wednesday, 04'th Mar 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide
02:04pm, Thursday, 26'th Feb 2026
Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. IRWD declined to exercise its option on CNP-104 for PBC after disappointing data,
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
11:41am, Thursday, 26'th Feb 2026
Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
02:27pm, Wednesday, 25'th Feb 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
01:15pm, Wednesday, 25'th Feb 2026
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) an
What's in Store for These 5 Medical Companies This Earnings Season?
10:11am, Monday, 23'rd Feb 2026
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.6% – Here’s What Happened
04:36am, Sunday, 22'nd Feb 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) was down 5.6% on Friday. The stock traded as low as $4.40 and last traded at $4.3540. Approximately 302,776 shares traded hands during t
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
12:01pm, Friday, 20'th Feb 2026
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
04:21pm, Wednesday, 18'th Feb 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. East
IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?
11:35am, Thursday, 12'th Feb 2026
Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.
